Immunotherapy drug delays recurrence in kidney cancer patients
An immunotherapy drug given after surgery improved disease-free survival rates in patients with kidney cancer at high risk of relapse.
Interim results of a phase 3 trial of adjuvant therapy revealed a 32% decrease in the risk of recurrence or death with pembrolizumab compared with a placebo
This is the first positive study of immunotherapy in patients with kidney cancer at high risk of relapse.
BOSTON -- Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim ...












